---
document_datetime: 2025-12-02 05:37:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/niapelf.html
document_name: niapelf.html
version: success
processing_time: 0.1094502
conversion_datetime: 2025-12-24 00:12:42.185491
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Niapelf

[RSS](/en/individual-human-medicine.xml/230705)

##### Authorised

This medicine is authorised for use in the European Union

paliperidone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Niapelf](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Niapelf is an antipsychotic medicine used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with paliperidone or risperidone.

Some patients whose symptoms have not yet been stabilised may still be given Niapelf if they have responded well to oral (by mouth) paliperidone or risperidone in the past, their symptoms are mild to moderate and a long-acting injectable treatment is needed.

Niapelf is a 'generic medicine'. This means that Niapelf contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Niapelf is Xeplion. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Niapelf contains the active substance paliperidone.

Expand section

Collapse section

## How is Niapelf used?

Niapelf is available as a prolonged-release suspension for injection in prefilled syringes. Prolonged-release means that the active substance is released slowly over a few weeks after being injected.

Treatment with Niapelf starts with two injections, given one week apart, followed by monthly maintenance injections. The first two injections are given into the deltoid muscle (upper part of the arm), while the maintenance doses can be given in the gluteal muscle (buttocks) or the deltoid muscle.

The medicine can only be obtained with a prescription.

For more information about using Niapelf, see the package leaflet or contact your doctor or pharmacist.

## How does Niapelf work?

The active substance in Niapelf, paliperidone, is an active metabolite (breakdown product) of risperidone, another antipsychotic medicine that has been used in the treatment of schizophrenia since the 1990s. In the brain, paliperidone attaches to several different receptors (targets) on nerve cells. This disrupts signals transmitted between brain cells by neurotransmitters, chemicals that allow nerve cells to communicate with each other. Paliperidone acts mainly by blocking receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin), which are involved in schizophrenia. By blocking these receptors, paliperidone helps to normalise the activity of the brain and reduce symptoms of the disease.

Paliperidone has been authorised in the European Union as Invega since 2007, as an oral treatment for schizophrenia. In Niapelf, paliperidone has been attached to a fatty acid that allows it to be released slowly after being injected. This allows the injection to have a long duration of action.

## How has Niapelf been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Xeplion, and do not need to be repeated for Niapelf.

As for every medicine, the company provided studies on the quality of Niapelf. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Niapelf?

Because Niapelf is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Niapelf authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Niapelf has been shown to have comparable quality and to be bioequivalent to Xeplion. Therefore, the Agency's view was that, as for Xeplion, the benefits of Niapelf outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Niapelf?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Niapelf have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Niapelf are continuously monitored. Suspected side effects reported with Niapelf are carefully evaluated and any necessary action taken to protect patients.

## Other information about Niapelf

Niapelf received a marketing authorisation valid throughout the EU on 21 March 2024.

This overview was last updated in 04-2024.

Niapelf : EPAR - Medicine overview

Reference Number: EMEA/H/C/006185

English (EN) (144.35 KB - PDF)

**First published:** 04/04/2024

[View](/en/documents/overview/niapelf-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-272)

български (BG) (167.63 KB - PDF)

**First published:**

04/04/2024

[View](/bg/documents/overview/niapelf-epar-medicine-overview_bg.pdf)

español (ES) (144.1 KB - PDF)

**First published:**

04/04/2024

[View](/es/documents/overview/niapelf-epar-medicine-overview_es.pdf)

čeština (CS) (164.06 KB - PDF)

**First published:**

04/04/2024

[View](/cs/documents/overview/niapelf-epar-medicine-overview_cs.pdf)

dansk (DA) (143.63 KB - PDF)

**First published:**

04/04/2024

[View](/da/documents/overview/niapelf-epar-medicine-overview_da.pdf)

Deutsch (DE) (147.7 KB - PDF)

**First published:**

04/04/2024

[View](/de/documents/overview/niapelf-epar-medicine-overview_de.pdf)

eesti keel (ET) (140.96 KB - PDF)

**First published:**

04/04/2024

[View](/et/documents/overview/niapelf-epar-medicine-overview_et.pdf)

ελληνικά (EL) (166.32 KB - PDF)

**First published:**

04/04/2024

[View](/el/documents/overview/niapelf-epar-medicine-overview_el.pdf)

français (FR) (145.01 KB - PDF)

**First published:**

04/04/2024

[View](/fr/documents/overview/niapelf-epar-medicine-overview_fr.pdf)

hrvatski (HR) (162.67 KB - PDF)

**First published:**

04/04/2024

[View](/hr/documents/overview/niapelf-epar-medicine-overview_hr.pdf)

italiano (IT) (141.92 KB - PDF)

**First published:**

04/04/2024

[View](/it/documents/overview/niapelf-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (171.12 KB - PDF)

**First published:**

04/04/2024

[View](/lv/documents/overview/niapelf-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.34 KB - PDF)

**First published:**

04/04/2024

[View](/lt/documents/overview/niapelf-epar-medicine-overview_lt.pdf)

magyar (HU) (164.64 KB - PDF)

**First published:**

04/04/2024

[View](/hu/documents/overview/niapelf-epar-medicine-overview_hu.pdf)

Malti (MT) (165.26 KB - PDF)

**First published:**

04/04/2024

[View](/mt/documents/overview/niapelf-epar-medicine-overview_mt.pdf)

Nederlands (NL) (144.77 KB - PDF)

**First published:**

04/04/2024

[View](/nl/documents/overview/niapelf-epar-medicine-overview_nl.pdf)

polski (PL) (166.89 KB - PDF)

**First published:**

04/04/2024

[View](/pl/documents/overview/niapelf-epar-medicine-overview_pl.pdf)

português (PT) (144.37 KB - PDF)

**First published:**

04/04/2024

[View](/pt/documents/overview/niapelf-epar-medicine-overview_pt.pdf)

română (RO) (159.36 KB - PDF)

**First published:**

04/04/2024

[View](/ro/documents/overview/niapelf-epar-medicine-overview_ro.pdf)

slovenčina (SK) (164.13 KB - PDF)

**First published:**

04/04/2024

[View](/sk/documents/overview/niapelf-epar-medicine-overview_sk.pdf)

slovenščina (SL) (161.57 KB - PDF)

**First published:**

04/04/2024

[View](/sl/documents/overview/niapelf-epar-medicine-overview_sl.pdf)

Suomi (FI) (140.83 KB - PDF)

**First published:**

04/04/2024

[View](/fi/documents/overview/niapelf-epar-medicine-overview_fi.pdf)

svenska (SV) (141.75 KB - PDF)

**First published:**

04/04/2024

[View](/sv/documents/overview/niapelf-epar-medicine-overview_sv.pdf)

Niapelf : EPAR - Risk Management Plan

English (EN) (200.44 KB - PDF)

**First published:** 04/04/2024

[View](/en/documents/rmp/niapelf-epar-risk-management-plan_en.pdf)

## Product information

Niapelf : EPAR - All Authorised Presentations

English (EN) (17.77 KB - PDF)

**First published:** 04/04/2024

[View](/en/documents/product-information/niapelf-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-375)

български (BG) (58.41 KB - PDF)

**First published:**

04/04/2024

[View](/bg/documents/product-information/niapelf-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.39 KB - PDF)

**First published:**

04/04/2024

[View](/es/documents/product-information/niapelf-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.14 KB - PDF)

**First published:**

04/04/2024

[View](/cs/documents/product-information/niapelf-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.18 KB - PDF)

**First published:**

04/04/2024

[View](/da/documents/product-information/niapelf-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (47.34 KB - PDF)

**First published:**

04/04/2024

[View](/de/documents/product-information/niapelf-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.9 KB - PDF)

**First published:**

04/04/2024

[View](/et/documents/product-information/niapelf-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.88 KB - PDF)

**First published:**

04/04/2024

[View](/el/documents/product-information/niapelf-epar-all-authorised-presentations_el.pdf)

français (FR) (46.44 KB - PDF)

**First published:**

04/04/2024

[View](/fr/documents/product-information/niapelf-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.11 KB - PDF)

**First published:**

04/04/2024

[View](/hr/documents/product-information/niapelf-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.13 KB - PDF)

**First published:**

04/04/2024

[View](/is/documents/product-information/niapelf-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.88 KB - PDF)

**First published:**

04/04/2024

[View](/it/documents/product-information/niapelf-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.92 KB - PDF)

**First published:**

04/04/2024

[View](/lv/documents/product-information/niapelf-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.85 KB - PDF)

**First published:**

04/04/2024

[View](/lt/documents/product-information/niapelf-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.6 KB - PDF)

**First published:**

04/04/2024

[View](/hu/documents/product-information/niapelf-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.51 KB - PDF)

**First published:**

04/04/2024

[View](/mt/documents/product-information/niapelf-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.33 KB - PDF)

**First published:**

04/04/2024

[View](/nl/documents/product-information/niapelf-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.37 KB - PDF)

**First published:**

04/04/2024

[View](/no/documents/product-information/niapelf-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.36 KB - PDF)

**First published:**

04/04/2024

[View](/pl/documents/product-information/niapelf-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.23 KB - PDF)

**First published:**

04/04/2024

[View](/pt/documents/product-information/niapelf-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.26 KB - PDF)

**First published:**

04/04/2024

[View](/ro/documents/product-information/niapelf-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.15 KB - PDF)

**First published:**

04/04/2024

[View](/sk/documents/product-information/niapelf-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.51 KB - PDF)

**First published:**

04/04/2024

[View](/sl/documents/product-information/niapelf-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (42.94 KB - PDF)

**First published:**

04/04/2024

[View](/fi/documents/product-information/niapelf-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.55 KB - PDF)

**First published:**

04/04/2024

[View](/sv/documents/product-information/niapelf-epar-all-authorised-presentations_sv.pdf)

Niapelf : EPAR - Product information

English (EN) (1018.63 KB - PDF)

**First published:** 04/04/2024

[View](/en/documents/product-information/niapelf-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-670)

български (BG) (1.18 MB - PDF)

**First published:**

04/04/2024

[View](/bg/documents/product-information/niapelf-epar-product-information_bg.pdf)

español (ES) (736.56 KB - PDF)

**First published:**

04/04/2024

[View](/es/documents/product-information/niapelf-epar-product-information_es.pdf)

čeština (CS) (1.71 MB - PDF)

**First published:**

04/04/2024

[View](/cs/documents/product-information/niapelf-epar-product-information_cs.pdf)

dansk (DA) (1.37 MB - PDF)

**First published:**

04/04/2024

[View](/da/documents/product-information/niapelf-epar-product-information_da.pdf)

Deutsch (DE) (1.01 MB - PDF)

**First published:**

04/04/2024

[View](/de/documents/product-information/niapelf-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

04/04/2024

[View](/et/documents/product-information/niapelf-epar-product-information_et.pdf)

ελληνικά (EL) (1.91 MB - PDF)

**First published:**

04/04/2024

[View](/el/documents/product-information/niapelf-epar-product-information_el.pdf)

français (FR) (1.17 MB - PDF)

**First published:**

04/04/2024

[View](/fr/documents/product-information/niapelf-epar-product-information_fr.pdf)

hrvatski (HR) (1.02 MB - PDF)

**First published:**

04/04/2024

[View](/hr/documents/product-information/niapelf-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

04/04/2024

[View](/is/documents/product-information/niapelf-epar-product-information_is.pdf)

italiano (IT) (957.17 KB - PDF)

**First published:**

04/04/2024

[View](/it/documents/product-information/niapelf-epar-product-information_it.pdf)

latviešu valoda (LV) (2.11 MB - PDF)

**First published:**

04/04/2024

[View](/lv/documents/product-information/niapelf-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.18 MB - PDF)

**First published:**

04/04/2024

[View](/lt/documents/product-information/niapelf-epar-product-information_lt.pdf)

magyar (HU) (1.96 MB - PDF)

**First published:**

04/04/2024

[View](/hu/documents/product-information/niapelf-epar-product-information_hu.pdf)

Malti (MT) (884.06 KB - PDF)

**First published:**

04/04/2024

[View](/mt/documents/product-information/niapelf-epar-product-information_mt.pdf)

Nederlands (NL) (955.99 KB - PDF)

**First published:**

04/04/2024

[View](/nl/documents/product-information/niapelf-epar-product-information_nl.pdf)

norsk (NO) (1.41 MB - PDF)

**First published:**

04/04/2024

[View](/no/documents/product-information/niapelf-epar-product-information_no.pdf)

polski (PL) (1.22 MB - PDF)

**First published:**

04/04/2024

[View](/pl/documents/product-information/niapelf-epar-product-information_pl.pdf)

português (PT) (1.63 MB - PDF)

**First published:**

04/04/2024

[View](/pt/documents/product-information/niapelf-epar-product-information_pt.pdf)

română (RO) (1.96 MB - PDF)

**First published:**

04/04/2024

[View](/ro/documents/product-information/niapelf-epar-product-information_ro.pdf)

slovenčina (SK) (1.44 MB - PDF)

**First published:**

04/04/2024

[View](/sk/documents/product-information/niapelf-epar-product-information_sk.pdf)

slovenščina (SL) (1.46 MB - PDF)

**First published:**

04/04/2024

[View](/sl/documents/product-information/niapelf-epar-product-information_sl.pdf)

Suomi (FI) (1.37 MB - PDF)

**First published:**

04/04/2024

[View](/fi/documents/product-information/niapelf-epar-product-information_fi.pdf)

svenska (SV) (1.36 MB - PDF)

**First published:**

04/04/2024

[View](/sv/documents/product-information/niapelf-epar-product-information_sv.pdf)

21/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Niapelf Active substance paliperidone palmitate International non-proprietary name (INN) or common name paliperidone Therapeutic area (MeSH) Schizophrenia Anatomical therapeutic chemical (ATC) code N05AX13

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

indicated for maintenance treatment of schizophrenia in adult patients stabilised withpaliperidone or risperidone.

In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Niapelf may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

## Authorisation details

EMA product number EMEA/H/C/006185

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Neuraxpharm Pharmaceuticals S.L.

Avinguda De Barcelona 69 Poligono Industrialde La Fuensanta 08970 Sant Joan Despi SPAIN

Opinion adopted 25/01/2023 Marketing authorisation issued 31/03/2024

## Assessment history

## Initial marketing authorisation documents

Niapelf : EPAR - Public assessment report

Adopted

Reference Number: EMA/100717/2024

English (EN) (903.88 KB - PDF)

**First published:** 25/04/2024

[View](/en/documents/assessment-report/niapelf-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Niapelf

Adopted

Reference Number: EMA/CHMP/18799/2024

English (EN) (131.24 KB - PDF)

**First published:** 26/01/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-niapelf_en.pdf)

#### News on Niapelf

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024) 26/01/2024

**This page was last updated on** 04/04/2024

## Share this page

[Back to top](#main-content)